Michelle Nelken has 25 years experience in the pharmaceutical and biotechnology industry managing early and late phase clinical studies. She has spent the majority of her career developing clinical programs in rare indications for small biotechnology companies. Earlier in her career Michelle spent 4 years with Alexion (formerly Enobia) as the Director of Clinical Operations leading to the successful approval of Strensiq® for the treatment of hypophosphatasia an ultra-rare metabolic disorder. Prior to this she spent 2 years at Genzyme working on enzyme replacement therapies for lysosomal storage disorders and diagnostic studies and contributed to the regulatory approvals of Myozyme® for treatment of Pompe disease and the OSOM® Trichomonas Rapid Test. Michelle started her career at Biogen managing nonclinical studies in psoriasis that led to the regulatory approval of Amevive®. She earned her Bachelor of Science in Nutrition from the University of Maine.
